問卷

TPIDB > Principal Investigator

Principal Investigator


Hualien Tzu Chi Hospital

Division of Hematology & Oncology

Division of General Surgery

更新時間:2024-02-21

張群明
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

篩選

List

2Cases

2023-05-01 - 2027-05-31

Phase III

Active
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
  • Condition/Disease

    Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting

  • Test Drug

    injection

Participate Sites
13Sites

Not yet recruiting9Sites

Recruiting4Sites

2024-03-01 - 2030-09-20

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites